prostate cancer
Conditions
Interventions
High frequency irreversible electroporation combined with endocrine therapy:High frequency irreversible electroporation combined with endocrine therapy
Endocrine therapy alone:Endocrine therapy alone
Sponsors
Shanghai East Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Fully understand the treatment plan for irreversible electroporation and sign informed consent; 2. The patient is diagnosed with metastatic prostate cancer and intends to undergo endocrine therapy; 3. Age range of 40-90 years old.
Exclusion criteria
Exclusion criteria: 1. Patients with severe arrhythmia, who are assessed by the anesthesiology department to have contraindications for anesthesia or high-risk intraoperative placement of cardiac pacemakers; 2. Patients with implanted cardiac pacemakers; 3. Other tumors of the urinary system, such as bladder cancer, kidney cancer, and ureteral cancer;Patients with malignant tumors in other parts of the body, for whom researchers cannot assess their long-term survival or whether it is affected;or patients in acute infection period or other severe infection (including active hepatitis B or C virus infection, urinary system infection);Patients with HIV-positive; 4. Patients with a history of epilepsy; 5. Patients with other serious systemic diseases that the researchers believe may interfere with the treatment, evaluation and compliance of this trial; 6. Patients who have participated in other clinical trials within three months; 7. ASA classification of 4 or above, such as patients with malignant hypertension, recent myocardial infarction, active stage of cerebrovascular accident, severe anemia, and other contraindications to elective surgery under general anesthesia; 8. Patients who are judged by the researchers to be unfit for participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PSA progression free survival period;Whole machine stability assessment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Median survival period;Disease progression time;Time-to-Treatment Failure;Adverse event;Combination medication; | — |
Countries
China
Contacts
Public ContactHaifeng Wang
Shanghai East Hospital
Outcome results
None listed